Affordable Access

Doxazosin--an alpha-1 receptor blocking agent in the long-term management of benign prostatic hyperplasia (BPH) (Part Two).

Authors
Type
Published Article
Journal
International urology and nephrology
Publication Date
Volume
27
Issue
4
Pages
413–417
Identifiers
PMID: 8586513
Source
Medline

Abstract

This part of our study presents results of laboratory evaluations in patients with BPH during treatment with prazosin and doxazosin. After 72 weeks serum PSA and PAP fell by 40.2% and 82%, respectively. Blood urea nitrogen concentration decreased by 28.5% and serum creatinine by 20.8%. The results confirm long-term favourable effects of the therapy of patients with BPH.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments